Fierce Pharma September 7, 2023
Now that the Centers for Medicare & Medicaid Services (CMS) has revealed its list of the first 10 drugs subject to Medicare price negotiations under the Inflation Reduction Act (IRA), it’s time to consider the financial implications for the affected companies.
In 2026, the initial year of Medicare price negotiations, the overall impact will be “modest,” according to a recent report from Moody’s Investors Service. But for some companies, the pain could be more acute.
Industrywide, the financial effects of the negotiations will grow over time. In 2027 and 2028, 15 drugs will be added to the list each year, leading to 2031 when 100 drugs will be subject to price negotiations.
The product most impacted...
Today's Sponsors
Today's Sponsor